JP2010536849A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536849A5
JP2010536849A5 JP2010521817A JP2010521817A JP2010536849A5 JP 2010536849 A5 JP2010536849 A5 JP 2010536849A5 JP 2010521817 A JP2010521817 A JP 2010521817A JP 2010521817 A JP2010521817 A JP 2010521817A JP 2010536849 A5 JP2010536849 A5 JP 2010536849A5
Authority
JP
Japan
Prior art keywords
isopropoxyethyl
thioxo
pyrrolo
tetrahydro
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521817A
Other languages
English (en)
Japanese (ja)
Other versions
JP5247804B2 (ja
JP2010536849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2008/050950 external-priority patent/WO2009025618A1/en
Publication of JP2010536849A publication Critical patent/JP2010536849A/ja
Publication of JP2010536849A5 publication Critical patent/JP2010536849A5/ja
Application granted granted Critical
Publication of JP5247804B2 publication Critical patent/JP5247804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521817A 2007-08-23 2008-08-22 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 Active JP5247804B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
US60/957,523 2007-08-23
US60/957,525 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013080125A Division JP2013151547A (ja) 2007-08-23 2013-04-08 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Publications (3)

Publication Number Publication Date
JP2010536849A JP2010536849A (ja) 2010-12-02
JP2010536849A5 true JP2010536849A5 (OSRAM) 2012-10-11
JP5247804B2 JP5247804B2 (ja) 2013-07-24

Family

ID=40378392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521817A Active JP5247804B2 (ja) 2007-08-23 2008-08-22 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤
JP2013080125A Pending JP2013151547A (ja) 2007-08-23 2013-04-08 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013080125A Pending JP2013151547A (ja) 2007-08-23 2013-04-08 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Country Status (25)

Country Link
US (6) US20090054468A1 (OSRAM)
EP (1) EP2200616B1 (OSRAM)
JP (2) JP5247804B2 (OSRAM)
KR (1) KR101588464B1 (OSRAM)
CN (4) CN105687199A (OSRAM)
AU (1) AU2008289653B2 (OSRAM)
BR (1) BRPI0815681A2 (OSRAM)
CA (1) CA2698205C (OSRAM)
CY (1) CY1113714T1 (OSRAM)
DK (1) DK2200616T3 (OSRAM)
EA (1) EA017510B1 (OSRAM)
ES (1) ES2399846T3 (OSRAM)
HR (1) HRP20130139T1 (OSRAM)
IL (2) IL203738A (OSRAM)
ME (1) ME01510B (OSRAM)
MX (1) MX2010001983A (OSRAM)
MY (1) MY155633A (OSRAM)
NZ (1) NZ584135A (OSRAM)
PH (1) PH12014501180A1 (OSRAM)
PL (1) PL2200616T3 (OSRAM)
PT (1) PT2200616E (OSRAM)
RS (1) RS52665B (OSRAM)
SI (1) SI2200616T1 (OSRAM)
WO (1) WO2009025618A1 (OSRAM)
ZA (1) ZA201000848B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2776405A1 (en) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
WO2013144088A1 (en) * 2012-03-29 2013-10-03 Basf Se N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
MX382097B (es) 2015-05-05 2025-03-13 Pfizer 1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, y el uso del mismo para tratar afecciones cardiovasculares.
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
KR102705858B1 (ko) * 2017-07-17 2024-09-10 아스트라제네카 아베 의약에서의 사용을 위한 mpo 억제제
US20240067651A1 (en) * 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
KR20220149709A (ko) * 2020-03-05 2022-11-08 바이오하벤 테라퓨틱스 리미티드 골수 세포형과산화효소 저해제를 사용한 근위축성 측삭 경화증의 치료 방법
IL297857A (en) * 2020-05-06 2023-01-01 Biohaven Therapeutics Ltd Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
TW202426450A (zh) 2022-08-18 2024-07-01 瑞典商阿斯特捷利康公司 髓過氧化物酶抑制劑
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation
EP4624473A1 (en) * 2022-12-09 2025-10-01 Shenzhen Salubris Pharmaceuticals Co., Ltd. Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
US20040198753A1 (en) * 2002-01-28 2004-10-07 Hiroshi Kase Methods of treating patients suffering from movement disorders
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Similar Documents

Publication Publication Date Title
JP2010536849A5 (OSRAM)
IL203738A (en) Use of 1- (2-Isopropoxyethyl) -2-Theoxo-1, 2, 3, 5-Tetrahydro-Pyrolo [3, 2-d] Pyrimidine-4-On or its Acceptable Pharmaceutical Salt for the Preparation of a Multi-Systemic Degenerative Drug
JP2010529118A5 (OSRAM)
JP2009537554A5 (OSRAM)
JP2016539156A5 (OSRAM)
IL196854A (en) Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HRP20180942T1 (hr) Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima
JP2015515475A5 (OSRAM)
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
JP2012532874A5 (OSRAM)
FI3628319T3 (fi) Hepaattisen enkefalopatian hoito rifaksimiinilla
PH12013500172A1 (en) Use of binders for manufacturing storage stable formulations
HRP20180237T4 (hr) Metode za liječenje hcv-a
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
JP2010535814A5 (OSRAM)
NZ714963A (en) Compositions and methods for treating anemia
JP2011522816A5 (OSRAM)
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2012136529A5 (OSRAM)
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood